Comparison genetic profiling between myelodysplastic syndrome (MDS) and pre-MDS

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20240405004

Enrollment

328

Registered

2024-04-05

Start date

2023-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The patients 18 years and older who were diagnosed with MDS or pre-MDS between and have next-generation sequencing (NGS) results. Myelodysplastic syndrome ,pre-Myelodysplastic syndrome ,genetic mutation ,low-dose erythropoietin therapy

Interventions

1.Patients aged above 18 years. 2.Patients diagnosed with MDS 3. Patients with bone marrow study and next-generation sequencing (NGS) results,1.Patients aged above 18 years. 2.Patients diagnosed with

Diagnostic,Diagnostic

Patients diagnosed with MDS ,Patients diagnosed with pre-MDS

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Patients aged above 18 years. 2.Patients diagnosed with MDS or pre-MDS. 3. Patients with bone marrow study and next-generation sequencing (NGS) results

Exclusion criteria

Exclusion criteria: From the review bone marrow study, the result cannot be concluded to MDS or pre-MDS

Design outcomes

Primary

Measure	Time frame
To compare the genetic profiling between MDS and pre-MDS first visit To evaluate genetic mutations	—

Secondary

Measure	Time frame
To evaluate factors associated with well response first visit Low-dose ESA less than 10,000 units/week in in pre-MDS patients	—

Countries

Thailand

Contacts

Public ContactWeerapat Owattanapanich

Faculty of Medicine Siriraj Hospital, Mahidol University.

weerapato36733@gmail.com0891081983

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026